Efficacy and Safety of Regorafenib with or without PD-1 Inhibitors as Second-Line Therapy for Advanced Hepatocellular Carcinoma in Real-World Clinical Practice

BACKGROUND: Regorafenib is the first oral targeted drug as a second-line agent in patients with advanced hepatocellular carcinoma (HCC) who progressed on sorafenib treatment. Recently, several studies demonstrated that the combination of regorafenib and PD-1 inhibitors showed a synergistic effect. O...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Kan, Wu, Jianbing, Xu, Yongkang, Li, Dan, Huang, Shenlang, Mao, Ye
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9534176/
https://www.ncbi.nlm.nih.gov/pubmed/36212725
http://dx.doi.org/10.2147/OTT.S383685

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9534176/
https://www.ncbi.nlm.nih.gov/pubmed/36212725
http://dx.doi.org/10.2147/OTT.S383685

Ejemplares similares